Predicting response to a HER inhibitor
AssigneesGenentech, Inc., Hoffmann-La Roche Inc.
InventorsLukas C. Amler, Merrill Birkner, Chin-Yu Lin, Joachim Moecks, Andreas Strauss
Life of this patent
Estimating the term…
Abstract
The present application describes the use of low HER3 as a selection criterion for treating patients with a HER inhibitor, such as pertuzumab. It also describes the use of high HER2:HER3 ratio as a selection criterion for treating cancer patients, such as ovarian cancer patients, with a HER inhibitor, such as pertuzumab. In addition, the application describes the use of high HER3 as a selection criterion for treating cancer patients with a chemotherapeutic agent, for instance gemcitabine.
Claims23
A method for treating a patient with a type of cancer which is able to respond to a HER2 dimerization inhibitor antibody, comprising administering to the patient a therapeutically effective amount the HER2 antibody, wherein the patient's cancer has been determined to express HER3 at a level less than the median level for HER3 expression in the cancer type, and wherein the HER2 antibody comprises the variable light and variable heavy amino acid sequences in SEQ ID Nos. 3 and 4, respectively.
A method for treating a patient with a type of cancer which is able to respond to pertuzumab, comprising administering to the patient a therapeutically effective amount of pertuzumab, wherein the patient's cancer has been determined to express HER3 at a level less than the median level for HER3 expression in the cancer type.
A method for treating a patient with a type of cancer which is able to respond to a HER2 dimerization inhibitor antibody that binds to a heterodimeric binding site of HER2, comprising administering to the patient a therapeutically effective amount the HER2 antibody, wherein the patient's cancer has been determined to express HER3 at a level less than the median level for HER3 expression in the cancer type, and the wherein the cancer type is selected from the group consisting of ovarian cancer, peritoneal cancer, fallopian tube cancer, breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, and colorectal cancer.
A method for treating a patient with a type of cancer which is able to respond to pertuzumab, comprising administering to the patient a therapeutically effective amount of pertuzumab, wherein the patient's cancer has been determined to express HER3 at a level less than the median level for HER3 expression in the cancer type, and the wherein the cancer type is selected from the group consisting of ovarian cancer, peritoneal cancer, fallopian tube cancer, breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, and colorectal cancer.
Dependencies are inferred from the claim text.